top of page
Image by Warren Umoh
Screenshot 2024-09-15 at 19.19.40.png
image.png

GENOUS™ SUCCESS STORY

Long-term stability in a 74-year-old woman with gastric cancer

CHALLENGE

Just three months after starting Pembrolizumab, the patient’s condition worsened, raising concerns that her cancer was progressing. Her doctor considered stopping the treatment, thinking it might not be working.

At the age of 74, this female patient's battle against stomach cancer was extremely arduous. After undergoing radical surgery and adjuvant chemotherapy, her cancer still metastasized, forcing the treatment team to switch to Pembrolizumab.

Screenshot 2024-09-15 at 19.19.57.png

PRECISION CANCER SOLUTIONS

The patient’s molecular analysis revealed MMR (mismatch repair protein deficiency) and MSI-H (microsatellite instability high) status. These findings suggested that this was likely pseudoprogression—a temporary increase in tumor size due to immune cell infiltration—rather than true cancer cell growth. The Genomate report confirmed the possibility of pseudoprogression, providing important insights to guide next steps. The Molecular Tumor Panel recommended that the patient continue with Pembrolizumab, confident that the treatment was working as expected.

THE RIGHT DRUG. THE FIRST TIME. EVERYTIME

Based on the Genomate analysis, the treatment team decided to continue with the current regimen, and the patient's condition gradually stabilized. She continued to use Pembrolizumab, resulting in cancer control and improved quality of life.

For the treatment team, this means:

  • Higher success rate

  • Make decisions faster

  • Limit guesswork and side effects

  • Give patients the best treatment opportunities

OUTCOMES AND IMPACT OF TARGETED THERAPY

bottom of page